101 related articles for article (PubMed ID: 17020808)
1. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro.
Hägerkvist R; Makeeva N; Elliman S; Welsh N
Cell Biol Int; 2006 Dec; 30(12):1013-7. PubMed ID: 17020808
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning.
Hägerkvist R; Sandler S; Mokhtari D; Welsh N
FASEB J; 2007 Feb; 21(2):618-28. PubMed ID: 17135364
[TBL] [Abstract][Full Text] [Related]
3. Does the small tyrosine kinase inhibitor Imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?
Welsh N
Expert Opin Investig Drugs; 2012 Nov; 21(11):1743-50. PubMed ID: 22998750
[TBL] [Abstract][Full Text] [Related]
4. A protein tyrosine kinase inhibitor, imatinib mesylate (Gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats.
Gur S; Kadowitz PJ; Hellstrom WJ
J Sex Med; 2010 Oct; 7(10):3341-50. PubMed ID: 20584116
[TBL] [Abstract][Full Text] [Related]
5. Deletion of STAT-1 pancreatic islets protects against streptozotocin-induced diabetes and early graft failure but not against late rejection.
Callewaert HI; Gysemans CA; Ladrière L; D'Hertog W; Hagenbrock J; Overbergh L; Eizirik DL; Mathieu C
Diabetes; 2007 Aug; 56(8):2169-73. PubMed ID: 17473223
[TBL] [Abstract][Full Text] [Related]
6. c-Jun amino terminal kinase 1 deficient mice are protected from streptozotocin-induced islet injury.
Fukuda K; Tesch GH; Nikolic-Paterson DJ
Biochem Biophys Res Commun; 2008 Feb; 366(3):710-6. PubMed ID: 18082135
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.
Nurmio M; Toppari J; Zaman F; Andersson AM; Paranko J; Söder O; Jahnukainen K
Int J Androl; 2007 Aug; 30(4):366-76; discussion 376. PubMed ID: 17705809
[TBL] [Abstract][Full Text] [Related]
8. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
Mokhtari D; Welsh N
Clin Sci (Lond); 2009 Nov; 118(4):241-7. PubMed ID: 19886867
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
[TBL] [Abstract][Full Text] [Related]
11. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.
Ghanaat-Pour H; Sjöholm A
Diabetes Metab Res Rev; 2009 Feb; 25(2):163-84. PubMed ID: 19065603
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of imatinib mesylate in neuroblastoma xenografts.
Meco D; Riccardi A; Servidei T; Brueggen J; Gessi M; Riccardi R; Dominici C
Cancer Lett; 2005 Oct; 228(1-2):211-9. PubMed ID: 15950376
[TBL] [Abstract][Full Text] [Related]
13. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
15. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
16. c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase.
Kamath R; Jiang Z; Sun G; Yalowich JC; Baskaran R
Mol Pharmacol; 2007 Jan; 71(1):61-72. PubMed ID: 17021249
[TBL] [Abstract][Full Text] [Related]
17. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
18. Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML).
Tsapas A; Vlachaki E; Sarigianni M; Klonizakis F; Paletas K
Leuk Res; 2008 Apr; 32(4):674-5. PubMed ID: 17920117
[No Abstract] [Full Text] [Related]
19. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
20. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
